MedTrace Logo

Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC

NCT04360655 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-04-24

No results posted yet for this study

Summary

A randomized, prospective study of the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy versus anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention

Conditions

  • Effect Increased
  • Safety Issues

Interventions

PROCEDURE

bronchoscopic microwave intervention

bronchoscopic microwave intervention

DRUG

anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy

anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy

Sponsors & Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Principal Investigators

  • Caicun Zhou, MD, PHD · Shanghai Pulmonary Hospital, Shanghai, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2022-04-30
Completion
2023-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04360655 on ClinicalTrials.gov